1.38
+0.02(+1.47%)
Currency In USD
| Previous Close | 1.36 |
| Open | 1.42 |
| Day High | 1.42 |
| Day Low | 1.3 |
| 52-Week High | 1.96 |
| 52-Week Low | 1.13 |
| Volume | 73,831 |
| Average Volume | 77,628 |
| Market Cap | 67.82M |
| PE | -5.75 |
| EPS | -0.24 |
| Moving Average 50 Days | 1.52 |
| Moving Average 200 Days | 1.39 |
| Change | 0.02 |
If you invested $1000 in MediciNova, Inc. (MNOV) 10 years ago, it would be worth $248.2 as of March 10, 2026 at a share price of $1.38. Whereas If you bought $1000 worth of MediciNova, Inc. (MNOV) shares 5 years ago, it would be worth $157.89 as of March 10, 2026 at a share price of $1.38.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients
GlobeNewswire Inc.
Jan 29, 2026 11:00 PM GMT
LA JOLLA, Calif., Jan. 29, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that as of t
2026 New Year’s Greetings from the CEO
GlobeNewswire Inc.
Jan 06, 2026 2:00 PM GMT
LA JOLLA, Calif., Jan. 06, 2026 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (Nasdaq:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) provides shareholders a corpo
MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy
GlobeNewswire Inc.
Dec 18, 2025 11:00 AM GMT
LA JOLLA, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875), today announced the successf